Page 15 - Seelos Therapeutics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Seelos Therapeutics stock slides 58% after trial of treatment for suicidal ideation has too few patients to meet endpoint

Seelos Therapeutics Inc.’s stock tumbled 58% in premarket trade Wednesday, after the company reported promising results from a trial of a treatment for Acute.

Seelos therapeutics incSeelos therapeuticsAcute suicidal ideationMajor depressive disorderArticle normalRegulation government policyCorporate industrial newsSeelos therapeutics incS amp ampp 500 indexGovernment policyIndustrial news

Seelos Therapeutics: SLS-002 Phase II Study Fails To Meet Primary Endpoint On Limited Sample Size

Seelos Therapeutics: SLS-002 Phase II Study Fails To Meet Primary Endpoint On Limited Sample Size
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleBaden wübergRaj mehraSeelos therapeutics incMore such health newsAcute suicidal ideationMajor depressiveSeelos therapeutics

: Seelos Therapeutics stock slides 58% after trial of treatment for suicidal ideation has too few patients to meet endpoint

: Seelos Therapeutics stock slides 58% after trial of treatment for suicidal ideation has too few patients to meet endpoint
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Tim whitakerSeelos therapeutics incDrug administrationSeelos therapeuticsAcute suicidal ideationMajor depressive disorderMedical officer tim whitakerMarket pulse stories

Seelos Therapeutics, Inc Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Seelos Therapeutics, Inc. announced top line data demonstrating clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind,.

Seelos therapeutics incSeelos therapeuticsAcute suicidal ideationMajor depressive disorderDepression rating scaleDetailed summaryKey efficacy endpointsAdministered dissociative states scaleModified observerSedation scale

Gold Moves Higher; Fed Leaves Key Overnight Interest Rate Unchanged - Fresh Tracks Therapeutics (NASDAQ:FRTX), Cambridge (NASDAQ:CATC)

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 200 points on Wednesday. The Dow traded up 0.59% to 34,720.69 while the NASDAQ fell 0.07% to 13,668.37. The S&P 500 also rose, gaining, 0.17% to 4,451.42.

United kingdomCity ofSteelcase incPharmaceuticals incIcecure medical ltdEuropean unionSeelos therapeutics incCambridge bancorpDow jonesFresh tracks therapeutics incPeople bankLyft andStocks insiders areTracks therapeuticsComplete response letterNew drug application